Effects of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostatic hypertrophy induced with testosterone or dihydrotestosterone in a rat model: A randomized, controlled study

Current Therapeutic Research - Clinical and Experimental

Volumn 65, Issue 6, 2004, Pages 505-514

  Carbajal, Daisy ^a   Arruzazabala, Maria De Lourdes ^a   Más, Rosa ^a   Molina, Vivian ^a   Rodríguez, Eduardo ^a   González, Victor ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Benign prostatic hypertrophy; Dihydrotestosterone; Prostatic enlargement; Testosterone

Indexed keywords

ANDROSTANOLONE; CUBAN ROYAL PALM FRUIT EXTRACT; D 004; LIPID; PLANT EXTRACT; SOYBEAN OIL; TESTOSTERONE; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CALCULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CUBAN ROYAL PALM; DRUG EFFICACY; FRUIT; MALE; MEDICINAL PLANT; NONHUMAN; ORGAN WEIGHT; PH MEASUREMENT; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RAT;

EID: 14744293067     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2005.01.001     Document Type: Article

References (33)

1. Irani J, Brown CT, van der Meulen J, and Emberton M A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: Are all guidelines the same? BJU Int 92 2003 937 942
2. Oesterling JE Benign prostatic hyperplasia. Medical and minimally invasive treatment options N Engl J Med 332 1995 99 109
3. [published correction appears in BMJ. 2002;324:775] Barry MJ, and Roehrborn CG Benign prostatic hyperplasia BMJ 323 2001 1042 1046
4. Bhargava S, Canda AE, and Chapple CR A rational approach to benign prostatic hyperplasia evaluation: Recent advances Curr Opin Urol 14 2004 1 6
5. Djavan B, Remzi M, and Erne B The pathophysiology of benign prostatic hyperplasia Drug Today (Barc) 38 2002 867 876
6. Carson C III, and Rittmaster R The role of dihydrotestosterone in benign prostatic hyperplasia Urology 61 Suppl 1 2003 2 7
7. [in German] Bartsch G, Rittmaster RS, and Klocker H Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia Urologe A 41 2002 412 424
8. Sandhu JS, and Te AE The role of 5 alpha-reductase inhibition as monotherapy in view of the MTOPS data Curr Urol Rep 5 2004 274 279
9. Lam JS, Romas NA, and Lowe FC Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-Year follow-up Urology 61 2003 354 358
10. 1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia J Urol 171 2004 1029 1035
11. Kirby RS, Roehrborn CG, and Boyle P Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial Urology 61 2003 119 126
12. McConnell JD, Roehrborn CG, and Bautista OM The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 18 2003 2387 2398
13. Desgrandchamps F Who will benefit from combination therapy? The role of 5 alpha-reductase inhibitors and alpha blockade: A reflection from MTOPS Curr Opin Urol 14 2004 17 20
14. Andro MC, and Riffaud JP Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: A review of 25 years of published experience Curr Ther Res Clin Exp 56 1995 796 817
15. Carraro JC, Raynaud JP, and Koch G Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1098 patients Prostate 29 1996 231 240
16. Rhodes L, Primka RL, and Berman C Comparison of finasteride (Proscar), a 5-alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-alpha reductase inhibition Prostate 22 1993 43 51
17. Bombardelli E, Morazzoni P, and Small JK Serenoa repens (Bartram) Fitoterapia 68 1997 99 113
18. Plosker GL, and Brogden RN Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia Drugs Aging 9 1996 379 395
19. Wilt TJ, Ishani A, and Stark G Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review JAMA 280 1998 1604 1609
20. Gordon AE, and Shaughnessy AF Saw palmetto for prostate disorders Am Fam Physician 67 2003 1281 1283
21. Goepel M, Hecker U, and Krege S Saw palmetto extracts potently and non-competitively inhibit human alpha 1-adrenoceptors in vitro Prostate 38 1999 208 215
22. Marks LS, Partin AW, and Epstein JI Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia J Urol 163 2000 1451 1456
23. Carbin BE, Larsson B, and Lindahl O Treatment of benign prostatic hyperplasia with phytosterols Br J Urol 66 1990 639 641
24. Laguna A, Rodríguez E, González V, et al, inventors; Laboratorios Dalmer SA, assignee. Pharmaceutical composition and procedure for the prevention and treatment of prostate hyperplasia and prostatitis obtained from the fruits of Roystonea regia (Cuban royal palm). Cuba patent PCT/CU/2004/00004 (pending).
25. Arruzazabala ML, Carbajal D, Mas R, et al. Preventive effects of D-004, a lipid extract from Cuban royal palm (Rostonea regia) fruits, on prostate hyperplasia induced with testosterone on intact and castrated rodents. Drugs Exptl Res. In press.
26. Nakayama O, Hirosumi J, and Chida N FRI46687, a novel steroid 5 alpha-reductase inhibitor: In vitro and in vivo effects on prostates Prostate 31 1997 241 249
27. Pandita RK, Persson K, Hedlund P, and Andersson KE Testosterone-induced prostatic growth in the rat causes bladder overactivity unrelated to detrusor hypertrophy Prostate 35 1998 102 108
28. Paubert-Braquet M, Richardson FO, and Servent-Saez N Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat Pharmacol Res 34 1996 171 179
29. Mahapokai W, Van Sluijs FJ, and Schalken JA Models for studying benign prostatic hyperplasia Prostate Cancer Prostatic Dis 3 2000 28 33
30. Habib FK, Ross M, and Bayne CW Development of a new in vitro model for the study of benign prostatic hyperplasia Prostate Suppl 9 2000 15 20
31. Tutrone RF Jr, Ball RA, and Ornitz DM Benign prostatic hyperplasia in a transgenic mouse: A new hormonally sensitive investigatory model J Urol 149 1993 633 639
32. Deslypere JP, Young M, Wilson JD, and McPhaul MJ Testosterone and 5 α-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene Mol Cell Endocrinol 88 1992 15 22
33. Zhou ZX, Lane MV, and Kemppainen JA Specificity of ligand-dependent androgen receptor stabilization: Receptor domain interactions influence ligand dissociation and receptor stability Mol Endocrinol 9 1995 208 218